Committed to innovative surgical solutions

Contact us

Developing advanced energy-based surgical solutions

Our products improve the way surgeons treat breast cancer patients setting a new standard in post-lumpectomy patient care.
About Us

We are revolutionizing breast cancer treatment

Innoblative is a private medical device company addressing unmet clinical needs for patients with breast cancer and other soft tissue diseases. We are developing advanced energy-based surgical solutions to help improve the way surgeons coagulate and ablate post-surgical breast cancer and other soft tissue diseases to achieve better care for patients.


Learn more about Innoblative >

SIRA® is designed specifically for intraoperative coagulation and ablation of soft tissue. A single-use disposable applicator, the SIRA® device is used in conjunction with a radiofrequency electrosurgical generator to effectively ablate target tissue.

SIRA® has received FDA clearance and CE Mark approval. Innoblative has multiple platform devices in development.

SIRA®, A Novel Device Targeting The Challenges Of Breast-Conserving Surgery (BCS):

  1. Radiofrequency ablation is clinically proven to be safe and effective.
  2. Designed for radiofrequency ablation of the post-lumpectomy cavity during breast conserving surgery.
  3. Provides localized margin control to reduce the need for reoperation.
 

If you are interested in in participating in our Post Market Clinical Trial, contact us here.

Learn more

1 in 8 women will get breast cancer in their life¹

With over 80% of breast cancer patients being eligible for BCT, Innoblative is dedicated to providing cutting-edge solutions that prioritize patient care and well-being. This is where Innoblative is innovating by developing a revolutionary technology that aims to improve the outcome of breast conserving therapy.


Through our innovative approach, we are reshaping the landscape of breast cancer treatment and offering new hope to those in need.

Learn more

Recent Announcements

Join Us at RESI JPM 2025

When: January 14, 2025 Location: San Francisco, CA Details: The 50th RESI Conference will be held on January 14 at the San Francisco Marriott Marquis, featuring an in-person

Read More »
  1. https://www.cancer.gov/types/breast/risk-fact-sheet

You are now leaving this website

Any third-party link you select from this site may take you to an Innoblative website intended for US audiences or a website that is not affiliated with Innoblative.
I Agree